From the Division of Interventional Radiology (S.G.N., S.J.A., I.J.P., C.I., M.G.K., J.S.K., A.L.W., R.O.), Department of Radiology (K.S.Z., D.G.M.), and Division of Transplant Surgery (N.N.K., A.K.M.), Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054.
Radiographics. 2022 Oct;42(6):1705-1723. doi: 10.1148/rg.220011.
Liver transplant remains the definitive therapy for patients with end-stage liver disease. Outcomes have continued to improve, in part owing to interventions used to treat posttransplant complications involving the hepatic arteries, portal vein, hepatic veins or inferior vena cava (IVC), and biliary system. Significant hepatic artery stenosis can be treated with angioplasty or stent placement to prevent thrombosis and biliary ischemic complications. Hepatic arterioportal fistula and hepatic artery pseudoaneurysm are rare complications that can often be treated with endovascular means. Treatment of hepatic artery thrombosis can have mixed results. Portal vein stenosis can be treated with venoplasty or more commonly stent placement. The rarer portal vein thrombosis can also be treated with endovascular techniques. Hepatic venous outflow stenosis of the hepatic veins or IVC is amenable to venoplasty or stent placement. Complications of the bile ducts are the most encountered complication after liver transplant. When not amenable to endoscopic intervention, biliary stricture, bile leak, and ischemic cholangiopathy can be treated with percutaneous transhepatic cholangiography with biliary drainage and other interventions. New techniques have further improved care for these patients. Transsplenic portal vein recanalization has improved transplant candidacy for patients with chronic portal vein thrombosis. Spontaneous splenorenal shunt and splenic artery steal syndrome (nonocclusive hepatic artery hypoperfusion syndrome) remain complicated topics, and the role of endovascular embolization is developing. When patients have recurrence of cirrhosis after transplant, most commonly due to viral hepatitis, transjugular intrahepatic portosystemic shunt (TIPS) may be required to treat symptoms of portal hypertension. RSNA, 2022.
肝移植仍然是治疗终末期肝病患者的确定性疗法。由于采用了治疗涉及肝动脉、门静脉、肝静脉或下腔静脉(IVC)和胆道系统的移植后并发症的干预措施,其结果不断得到改善。严重的肝动脉狭窄可以通过血管成形术或支架置入术来治疗,以防止血栓形成和胆道缺血性并发症。肝动脉-门静脉瘘和肝动脉假性动脉瘤是罕见的并发症,通常可以通过血管内治疗来治疗。肝动脉血栓形成的治疗效果不一。门静脉狭窄可以通过血管成形术或更常见的支架置入术来治疗。更罕见的门静脉血栓形成也可以通过血管内技术治疗。肝静脉或 IVC 的肝静脉流出道狭窄可以通过血管成形术或支架置入术来治疗。胆管并发症是肝移植后最常见的并发症。当不能进行内镜干预时,可以通过经皮肝穿刺胆管造影和胆汁引流以及其他介入治疗来治疗胆管狭窄、胆漏和缺血性胆管炎。新技术进一步改善了这些患者的治疗效果。经脾门静脉再通改善了慢性门静脉血栓形成患者的移植候选资格。自发性脾肾分流和脾动脉盗血综合征(非闭塞性肝动脉低灌注综合征)仍然是复杂的问题,血管内栓塞的作用正在发展。当患者在移植后复发肝硬化时,大多数是由于病毒性肝炎,可能需要经颈静脉肝内门体分流术(TIPS)来治疗门静脉高压的症状。RSNA,2022 年。